Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M. · 2019

Read Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. by Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6326956.txt.

Introduction

Haubner and co-authors map pairs of surface markers on leukemia stem cells. Their study appeared in Leukemia. Acute myeloid leukemia, or AML, is hard to target cleanly. Its cells share markers with healthy blood cells. Minor clones can also survive and cause relapse. The team sought marker pairs found on leukemia but not normal tissue.

They profiled six markers in 356 patient samples. Normal bone marrow samples served as comparison. All six markers appeared widely on AML cells. Each also showed up somewhere in healthy blood making. Pairing markers changed the picture a lot. Two pairs, CD33 with TIM3 and CLL1 with TIM3, stood out. They were far stronger in AML than in healthy tissue. Such pairs could guide safer combination therapies.

Catalog record

CREATORHaubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6326956

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML By S. Haubner, F. Perna, T. Köhnke, C. Schmidt, S. Berman, C. Augsberger, F. M. Schnorfeil, C. Krupka, F. S. Lichtenegger, X. Liu, P. Kerbs, S. Schneider Published in: Leukemia DOI: 10.1038/s41375-018-0180-3 ABSTRACT Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that combinatorial targeting of AML cells can enhance therapeutic efficacy without increasing toxicity. To identify target antigen combinations specific for AML and leukemic stem cells, we generated a detailed protein expression profile based on flow cytometry of primary AML (n = 356) and normal bone marrow samples (n = 34), and a recently reported integrated normal tissue proteomic data set. We analyzed antigen expression levels of CD33, CD123, CLL1, TIM3, CD244 and CD7 on AML bulk and leukemic stem cells at initial diagnosis (n = 302) and relapse (n = 54). CD33, CD123, CLL1, TIM3 and CD244 were ubiquitously expressed on AML bulk cells at initial diagnosis and relapse, irrespective of genetic characteristics. For each analyzed target, we found additional expression in different populations of normal hematopoiesis. Analyzing the coexpression of our six targets in all dual combinations (n = 15), we found CD33/TIM3 and CLL1/TIM3 to be highly positive in AML compared with normal hematopoiesis and non-hematopoietic tissues. Our findings indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML. INTRODUCTION Despite some advances in the treatment of acute myeloid leukemia (AML) in recent years, overall prognosis remains poor [1]. Allogeneic stem cell transplantation is still the only curative option in high risk and relapsed AML, but morbidity and mortality are high owing to transplant-related side effects and refractory disease [2]. Targeted immunotherapy provides a potent option to specifically eliminate chemoresistant leukemic stem cells, which are reported to be the main cause of relapse [3]. In relapsed B-cell acute lymphoblastic leukemia (B-ALL), targeting of CD19 via bispecific T-cell-engaging antibody constructs and chimeric antigen receptor (CAR) T-cell products has shown remarkable antileukemic effects and a tolerable safety profile [4–10]. Given its success in B-ALL, the translation of T cell-based targeted immunotherapy to AML is of major interest and currently being evaluated in preclinical and clinical trials. However, choice of suitable target antigens in AML has proven to be challenging. In B-ALL, CD19 can be considered an ideal target antigen owing to its high expression on leukemic cells and its restricted expression profile on normal cells: it is expressed on essentially all B-lineage cells, whereas negative on all other hematopoietic lineages or other normal tissues [11, 12]. In line with the CD19 expression pattern, the on-target off-leukemia toxicity of CD19 CAR T-cell therapy is tolerable and limited to B-cell aplasia [13]. In AML, however, the most suitable target antigen still needs to be defined. Several surface-bound target antigens are known to be overexpressed on AML cells [14–32]. Some of these, including CD33, CD123, CLL1, CD47, CD96, CD157, CD244, TIM3 and CD7, have been reported to be expressed on leukemic stem cells (LSC) [20, 21, 24, 27, 32–36]. However, single-targeting approaches against these LSC-associated antigens is complicated as none of the antigens are exclusively expressed on AML cells, leading to severe on-target off-leukemia toxicity [37–40]. Furthermore, clonal heterogeneity or antigen escape mechanisms could lead to persistence of AML cells upon single-targeting therapy. Perna et al. [12] recently provided the rationale that a combinatorial targeting approach with well-matched target antigens could have the potential to enhance therapeutic efficacy without increasing on-target off-leukemia toxicity. In our study, we analyzed the coexpression profile of the most commonly targeted and leukemic stem cell-associated antigens within a single cohort of > 300 AML patients, comparing primary AML cells to normal hematopoietic cells and non-hematopoietic tissues. We sought to identify combinations of target antigens that show high coexpression in AML compared with normal cells and thereby provide options to reduce toxicity and overcome antigen escape mechanisms as well as clonal heterogeneity in AML. MATERIALS AND METHODS Patient samples and clinical data For flow cytometric analysis, peripheral blood or bone marrow aspirate samples of AML patients at initial diagnosis (n = 302) and relapse (n = 54) as well as bone marrow aspirates from healthy donors (n = 34) were used. Sample size was chosen based on feasibility and experience with previous analysis [34]. All samples were collected after written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig Maximilian University Munich. Patient characteristics are summarized in Table 1. Diagnostic workup to establish diagnosis of AML included cytomorphology, cytogenetics, fluorescence in situ hybridization, molecular genetics and immunophenotyping. Combined cytogenetic and molecular risk stratification groups were assigned in accordance with the Medical Research Council (MRC) and European LeukemiaNet (ELN) recommendations [41, 42].Table 1Patient characteristics of primary AML samples for flow cytometric analysisAll casesInitial DxRelapseSamples, n35630254Age, median (range)63 (16–92)65 (16–92)55 (23–80)Gender, n (%) Male201 (56%)170 (56%)31 (57%) Female155 (44%)132 (44%)23 (43%)FAB, n (%) M018 (8%)12 (7%)6 (19%) M168 (32%)61 (34%)7 (23%) M245 (21%)40 (22%)5 (16%) M39 (4%)8 (4%)1 (3%) M441 (19%)35 (19%)6 (19%) M530 (14%)24 (13%)6 (19%) M62 (1%)2 (1%)0 (0%) M70 (0%)0 (0%)0 (0%) Unknown14312023Cytogenetics, n (%) Normal karyotype139 (43%)123 (44%)16 (36%) Complex karyotype73 (23%)60 (21%)13 (30%) t(8;21)9 (3%)9 (3%)0 (0%) t(9;11)(p21-22;q23) or t(11;19)(q23;p13)10 (3%)9 (3%)1 (2%) inv(16)/t(16;16)(p13;q22)9 (3%)9 (3%)0 (0%) Other adverse risk abnormalities22 (7%)17 (6%)5 (11%) Non-classified abnormalities62 (19%)53 (19%)9 (20%) Unknown322210Mutations (normal karyotype), n (%) NPM1 mut/FLT3 wt38 (28%)37 (31%)1 (6%) NPM1 mut/FLT3-ITD35 (26%)30 (25%)5 (31%) NPM1 wt/FLT3-ITD14 (10%)14 (12%)0 (0%) NPM1 wt/FLT3 wt50 (36%)40 (33%)10 (63%) CEBPA mut6 (10%)6 (10%)0 (0%) KMT2A mut16 (12%)12 (10%)4 (22%)MRC, n (%) Favorable46 (14%)44 (16%)2 (4%) Intermediate178 (55%)154 (55%)24 (53%) Adverse100 (31%)81 (29%)19 (42%) Unknown32239ELN2010, n (%) Favorable64 (20%)62 (23%)2 (4%) Intermediate-I90 (28%)74 (27%)16 (36%) Intermediate-II64 (20%)55 (20%)9 (20%) Adverse100 (31%)82 (30%)18 (40%) Unknown38299 Flow cytometry After collection, all samples were analyzed immediately, without prior cryoconservation. Samples were stained with the following fluorochrome-conjugated anti-human monoclonal antibodies: CD7 (clone 8H8.1, Beckman Coulter, #A97050), CD33 (clone D3HL60.251, Beckman Coulter, #A54824), CD34 (clone 581, Beckman Coulter, #B49202), CD38 (clone LS198.4.3, Beckman Coulter, #B49200), CD45 (clone J.33, Beckman Coulter, #B36294), CD123 (clone 7G3, BD, #560087), CD244 (clone C1.7, Biolegend, #329508), TIM3 (clone 344823, R&D, #FAB2365A). Corresponding isotype controls were used for each sample. Surface antigen expression was assessed using a 10-color Navios flow cytometer (Beckman Coulter, Brea, CA, USA). Gating was performed as described in Supplemental Fig. 1A. As measure of antigen expression intensity, the median fluorescence intensity (MFI) ratio was used. MFI ratio was calculated by dividing the MFI value of the antigen-specific antibody by the MFI value of the respective isotype control (Supplemental Fig. 1B), as previously described [34]. We compared the isotype-based MFI ratio with an alternative MFI index, which is based on normalization to lymphocytes (Supplemental Fig. 2). The MFI ratio highly correlated with the MFI index for the myeloid-associated antigens CD33, CD123 and CLL1 (Spearman r > 0.88). In contrast, we observed no or lower correlation of the MFI ratio with the MFI index for the lymphoid-associated antigens TIM3, CD244

Read the complete text